Transcode Therapeutics Inc (RNAZ) — Tangible Net Worth Ratio
Transcode Therapeutics Inc (RNAZ) has a Tangible Net Worth Ratio of 17.4% as of June 2026. This metric is calculated by deducting intangible assets ($114.30 Million) from net assets ($138.36 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore Transcode Therapeutics Inc equity growth rate to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Transcode Therapeutics Inc Tangible Net Worth Ratio (2021–2025)
This chart shows how Transcode Therapeutics Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2025. As of June 2026, the ratio stands at 17.4%, reflecting net assets of $138.36 Million with intangible assets of $114.30 Million USD. Check Transcode Therapeutics Inc PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Annual Tangible Net Worth Ratio for Transcode Therapeutics Inc (2021–2025)
The table below presents the year-by-year Tangible Net Worth Ratio for Transcode Therapeutics Inc from 2021 to 2025, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see RNAZ market cap.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | -1005.9% | $10.34 Million | $114.30 Million | $162.40 Million | ▼ -1105.9 pp |
| 2023 | 100.0% | $1.64 Million | $0.00 | $5.17 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $3.24 Million | $0.00 | $7.59 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $20.40 Million | $0.00 | $22.94 Million | — |